2704. Real-world safety and effectiveness of letermovir for preventing cytomegalovirus (CMV) disease in patients undergoing allogenic hematopoietic stem cell transplantation (allo-HSCT): Final results of post-marketing surveillance (PMS) in Japan

BACKGROUND: CMV is one of the most common opportunistic infections in patients undergoing allo-HSCT. Letermovir is an inhibitor of CMV DNA terminase that is approved for CMV prophylaxis in patients undergoing allo-HSCT. We report the final results of a PMS that collected data on its safety and effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Fukuda, Masaki, Hattori, Junko, Ohkubo, Rika, Watanabe, Asuka, Maekawa, Shinichiroh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678032/
http://dx.doi.org/10.1093/ofid/ofad500.2315

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678032/
http://dx.doi.org/10.1093/ofid/ofad500.2315

Ejemplares similares